0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessAims Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta‐lactam antibiotics for serious Gram‐negative infections. Severe melioidosis ( Burkholderia pseudomallei infection) carries a mortality over 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis. Methods Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg −1 8 hourly by bolus injection or 4 mg kg −1 h −1 by constant infusion following a 12 mg kg −1 priming dose and pharmacokinetic and pharmacodynamic parameters were compared. Results Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC 90 of B. pseudomallei was 2 mg l −1 , giving a minimum target concentration (4*MIC) of 8 mg l −1 . The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half‐lives of ceftazidime were 0.468 (0.241–0.573) l kg −1 , 0.058 (0.005–0.159) l kg −1 h −1 and 7.74 (1.95–44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely ( r = 0.71; P < 0.001) and there was no evidence of significant nonrenal clearance. Conclusions Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure, which is common in patients with meliodosis is Clearance = k * creatinine clearance where k = 0.72. Calculation of a loading dose gives median (range) values of loading dose, D L of 18.7 mg kg −1 (9.5–23) and infusion rate I = 3.5 mg kg −1 h −1 (0.4–13) (which equals 84 mg kg −1 day −1 ). A nomogram for adjustment in renal failure is given.
Brian Angus, Michelle Smith, Yupin Suputtamongkol, H. Mattie, Amanda L. Walsh, Vanaporn Wuthiekanun, Wipada Chaowagul, Sir Nicholas White (2000). Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion <i>vs</i> intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology, 50(2), pp. 184-191, DOI: 10.1111/j.1365-2125.2000.00179.x.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2000
Authors
8
Datasets
0
Total Files
0
Language
English
Journal
British Journal of Clinical Pharmacology
DOI
10.1111/j.1365-2125.2000.00179.x
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access